Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 151 - 175 of 14890 in total
Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.
Approved
Experimental
Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron...
Approved
Matched Description: … chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and
Matched Categories: … Drugs for Treatment of Hyperkalemia and Hyperphosphatemia …
Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Description: … Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor.[A256408,A256413,L44758] Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is...
Approved
Investigational
Matched Description: … Bexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. ... to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and ... [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such …
Matched Categories: … Alimentary Tract and Metabolism …
Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.
Approved
Withdrawn
Matched Description: … Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. …
Matched Categories: … Cough and Cold Preparations …
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS...
Approved
Investigational
Matched Description: … a O-methyl group at the reducing end of the molecule. ... Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and ... It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they …
Matched Categories: … Blood and Blood Forming Organs …
Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. Darunavir is being...
Approved
Matched Description: … [A191682] Clinical trials are underway and are expected to conclude in August 2020.[L12066] …
Matched Categories: … darunavir and ritonavir ... darunavir and cobicistat ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat …
Matched Products: … Darunavir 600 and 800 mg …
Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … [L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic ... mixture of its active (R;R)- and inactive (S;S)-enantiomers. ... Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was …
Matched Mixtures name: … Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate ... Budesonide and Formoterol Fumarate Dihydrate …
Matched Categories: … formoterol and mometasone ... formoterol and budesonide ... formoterol and fluticasone ... formoterol and beclometasone ... formoterol and aclidinium bromide …
Olsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works...
Approved
Matched Description: … Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). ... , subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene ... [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase …
Matched Categories: … Alimentary Tract and Metabolism …
Approved
Illicit
Matched Categories: … Testosterone and derivatives …
Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Approved
Matched Description: … Sagamicin and Luxomicina. ... Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names …
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for...
Approved
Investigational
Matched Description: … embarrassment and a poor quality of life. ... Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social ... used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.
Approved
Investigational
Vet approved
Matched Description: … A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety …
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Antiinfectives and Antiseptics for Local Oral Treatment …
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, ... 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary …
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. ... rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and ... It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011 …
Matched Categories: … indacaterol and mometasone ... indacaterol and glycopyrronium bromide ... indacaterol, glycopyrronium bromide and mometasone …
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a …
Matched Categories: … Vaginal Creams, Foams, and Jellies ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Approved
Matched Description: … A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993,...
Approved
Investigational
Matched Description: … the face but on the back and chest as well [L4814]. ... of hair follicles and their accompanying sebaceous glands [L4814]. ... to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona …
Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
Approved
Matched Description: … It is used for treating migraines and tension headaches. …
Matched Mixtures name: … Isometheptene Mucate, Caffeine, and Acetaminophen ... Isometheptene Mucate, Caffeine, and Acetaminophen ... Isometheptene Mucate, Caffeine, and Acetaminophen …
Matched Categories: … Alimentary Tract and Metabolism …
Pantothenic acid, also called pantothenate or vitamin B5 (a B vitamin), is a water-soluble vitamin discovered by Roger J. Williams in 1919. For many animals, pantothenic acid is an essential nutrient as it is required to synthesize coenzyme-A (CoA), as well as to synthesize and metabolize proteins, carbohydrates, and fats....
Approved
Nutraceutical
Vet approved
Matched Description: … Pantothenic acid is the amide between pantoic acid and β-alanine and commonly found as its alcohol analog ... metabolize proteins, carbohydrates, and fats. ... , the provitamin panthenol, and as calcium pantothenate. …
Matched Mixtures name: … New Chapter's D'adamo 4 Your Type Multiple for Type O ... Multi Vitamin and Mineral vitamin ... Vitamin and Mineral Drink Mix …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Preparations for Treatment of Wounds and Ulcers …
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Matched Description: … An antiandrogen with about the same potency as cyproterone in rodent and canine species. …
Matched Categories: … Hormone Antagonists and Related Agents ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a degree...
Approved
Matched Description: … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both...
Approved
Investigational
Matched Description: … [L10833] This medication was first marketed in Russia and India before being granted FDA approval. ... [L1484] The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the ... [L10833] As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine …
Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and...
Approved
Investigational
Matched Description: … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April …
Displaying drugs 151 - 175 of 14890 in total